80 related articles for article (PubMed ID: 14583876)
41. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
[TBL] [Abstract][Full Text] [Related]
42. Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
Farrell DJ; Turner LL; Castanheira M; Jones RN
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):73-4. PubMed ID: 22819242
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
44. In vitro activity of moxifloxacin compared to other antimicrobials against streptococci isolated from iatrogenic oral bacteremia in Spain.
Tomás I; Alvarez M; Limeres J; Otero JL; Saavedra E; López-Meléndez C; Diz P
Oral Microbiol Immunol; 2004 Oct; 19(5):331-5. PubMed ID: 15327647
[TBL] [Abstract][Full Text] [Related]
45. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
[TBL] [Abstract][Full Text] [Related]
46. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Wenzler S; Schmidt-Eisenlohr E; Daschner F
Chemotherapy; 2004 Apr; 50(1):40-2. PubMed ID: 15084805
[TBL] [Abstract][Full Text] [Related]
47. In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
Norazah A; Lim VK; Rohani MY; Kamel AG
Med J Malaysia; 2005 Oct; 60(4):411-5. PubMed ID: 16570701
[TBL] [Abstract][Full Text] [Related]
48. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
Stein GE; Schooley SL; Peloquin CA; Kak V; Havlichek DH; Citron DM; Tyrrell KL; Goldstein EJ
Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775
[TBL] [Abstract][Full Text] [Related]
50. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.
Kanellakopoulou K; Pagoulatou A; Stroumpoulis K; Vafiadou M; Kranidioti H; Giamarellou H; Giamarellos-Bourboulis EJ
J Antimicrob Chemother; 2008 Jun; 61(6):1328-31. PubMed ID: 18353805
[TBL] [Abstract][Full Text] [Related]
52. Fourth-generation fluoroquinolone-resistant bacterial keratitis.
Jhanji V; Sharma N; Satpathy G; Titiyal J
J Cataract Refract Surg; 2007 Aug; 33(8):1488-9. PubMed ID: 17662450
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Cremades R; Rodríguez JC; García-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
J Antimicrob Chemother; 2011 Oct; 66(10):2281-3. PubMed ID: 21733966
[TBL] [Abstract][Full Text] [Related]
54. [Susceptibility test of the Mycobacterium avium complex to sixteen anti-infective agents].
Duan HF; Doi N; Li Q; Ma Y; Chen XY; Fu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2010 May; 33(5):359-62. PubMed ID: 20646615
[TBL] [Abstract][Full Text] [Related]
55. The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy.
Kowalski RP; Kowalski BR; Romanowski EG; Mah FS; Thompson PP; Gordon YJ
Am J Ophthalmol; 2006 Nov; 142(5):730-5. PubMed ID: 16978577
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives.
de Almeida MV; Saraiva MF; de Souza MV; da Costa CF; Vicente FR; Lourenço MC
Bioorg Med Chem Lett; 2007 Oct; 17(20):5661-4. PubMed ID: 17804222
[TBL] [Abstract][Full Text] [Related]
57. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin.
Govendir M; Hansen T; Kimble B; Norris JM; Baral RM; Wigney DI; Gottlieb S; Malik R
Vet Microbiol; 2011 Jan; 147(1-2):113-8. PubMed ID: 20619975
[TBL] [Abstract][Full Text] [Related]
58. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
Malik M; Drlica K
Antimicrob Agents Chemother; 2006 Aug; 50(8):2842-4. PubMed ID: 16870782
[TBL] [Abstract][Full Text] [Related]
59. Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
MacGowan AP; Reynolds R; Noel AR; Bowker KE
Antimicrob Agents Chemother; 2009 Dec; 53(12):5181-4. PubMed ID: 19805569
[TBL] [Abstract][Full Text] [Related]
60. Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Berger RE
J Urol; 2005 Jun; 173(6):1988-9. PubMed ID: 15879798
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
